US FDA approves Revolution Medicines' pancreatic cancer drug

Revolution Medicines Wins FDA Approval for Cancer Pill. What It Means for the Stock.

Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,’ has been granted approval in patients with pancreatic adenocarcinoma.

FDA Approves RevMed’s Breakthrough Pill for Pancreatic Cancer

Revolution Medicines Inc. secured US regulatory approval for its pancreatic cancer drug daraxonrasib, the first medicine to target one of the key molecular causes of the disease.

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines' targeted drug for adults with ​metastatic pancreatic cancer who have received prior treatment or ‌cannot receive combination chemotherapy.

FDA approves new pancreatic cancer drug expected to usher in new era of treatment

The FDA has approved a life-extending treatment for advanced pancreatic cancer — the first such therapy to attack a genetic cause of the highly lethal malignancy.

US FDA approves Revolution Medicines' pancreatic cancer drug

The U.S. Food and Drug Administration approved Revolution Medicines' targeted drug for metastatic pancreatic cancer, the regulator said on Wednesday. (Reporting by Padmanabhan Ananthan in Bengaluru;...

RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drug

The FDA granted the approval of Revolution Medicines' daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma 6.5 months ahead of deadline.